Update on nanoparticle albumin-bound paclitaxel.
Socinski
Mark
M
Medicine, Hematology and Oncology, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
D000068196:Albumin-Bound Paclitaxel; D000418:Albumins / Q000009:adverse effects / Q000737:chemistry / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000737:chemistry / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D004305:Dose-Response Relationship, Drug; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D053758:Nanoparticles / Q000009:adverse effects / Q000737:chemistry / Q000627:therapeutic use*; D017239:Paclitaxel / Q000009:adverse effects / Q000737:chemistry / Q000627:therapeutic use*; D012709:Serum Albumin / Q000009:adverse effects / Q000737:chemistry / Q000627:therapeutic use*
D000068196:Albumin-Bound Paclitaxel; D000418:Albumins; D000970:Antineoplastic Agents; D012709:Serum Albumin; D017239:Paclitaxel